EYPT EyePoint, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1314102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-66.5%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR-60.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-13,642.0%
Net margin-13,281.2%
FCF margin-11,599.4%
EBITDA margin-13,533.9%
Returns
ROE-221.9%
ROA-164.0%
ROIC (approx.)-368.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets34.7%
Debt / equity0.00x
Current ratio3.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue170.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $756,000 | $507,000 | $696,000 | $620,000 | $966,000 | $5.33M | $24.45M | $11.59M |
| R&D expense | $81.67M | $83.61M | $72.15M | $59.21M | $47.75M | $55.50M | $58.57M | $43.37M |
| SG&A expense | $15.41M | $14.24M | $15.24M | $11.38M | $14.49M | $11.86M | $13.88M | $12.59M |
| Operating income | -$96.88M | -$97.38M | -$87.23M | -$70.34M | -$62.02M | -$62.23M | -$48.84M | -$45.24M |
| Pretax income | -$95.61M | -$94.47M | — | -$67.42M | -$59.73M | -$59.33M | — | -$41.31M |
| Income tax | $0 | $0 | -$50,000 | $186,000 | $0 | $93,000 | $0 | $90,000 |
| Net income | -$95.61M | -$94.47M | -$84.83M | -$67.61M | -$59.73M | -$59.43M | -$45.20M | -$41.40M |
| EBITDA | -$96.11M | -$96.69M | -$86.59M | -$69.65M | -$61.45M | -$61.69M | -$48.34M | -$44.77M |
| EPS (basic) | -1.07 | -1.09 | -0.99 | — | -0.85 | -0.85 | -0.65 | — |
| EPS (diluted) | -1.07 | -1.09 | -0.99 | — | -0.85 | -0.85 | -0.65 | — |
| Weighted avg. shares (diluted) | 89,245 | 86,543 | 85,999 | — | 70,168 | 69,926 | 69,767 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $83.21M | $110.46M | $77.71M | $101.82M | $74.58M | $71.14M | $85.16M | $99.85M |
| Short-term investments | $35.01M | $70.01M | $144.83M | $204.26M | $129.44M | $184.59M | $233.04M | $271.21M |
| Inventory | $1.67M | $1.88M | $1.25M | $1.81M | $2.11M | $2.68M | $2.13M | $2.31M |
| Current assets | $126.99M | $188.82M | $249.50M | $328.65M | $216.11M | $265.25M | $326.98M | $383.31M |
| PP&E, net | $10.30M | $10.01M | $9.48M | $9.02M | $8.86M | $8.76M | $8.04M | $8.18M |
| Total assets | $166.14M | $228.19M | $288.22M | $364.00M | $251.69M | $301.15M | $362.56M | $418.46M |
| Current liabilities | $38.51M | $41.94M | $37.46M | $37.02M | $30.09M | $33.17M | $41.68M | $49.05M |
| Total liabilities | $57.63M | $61.78M | $57.74M | $57.88M | $51.51M | $55.14M | $64.17M | $81.96M |
| Shareholders' equity | $108.51M | $166.41M | $230.47M | $306.11M | $200.18M | $246.01M | $298.40M | $336.50M |
| Shares outstanding | 90.77M | 84.98M | 83.45M | 82.83M | 69.57M | 68.89M | 68.81M | 68.27M |
| Cash flow statement | ||||||||
| Operating cash flow | -$86.82M | -$62.35M | -$80.55M | -$65.05M | -$59.35M | -$62.59M | -$53.12M | -$35.85M |
| Capital expenditure | $1.21M | $1.20M | $997,000 | $986,000 | $798,000 | $1.22M | $276,000 | $384,000 |
| Free cash flow | -$88.02M | -$63.55M | -$81.55M | -$66.03M | -$60.15M | -$63.81M | -$53.40M | -$36.23M |
| Investing cash flow | $33.79M | $75.10M | $59.05M | -$74.67M | $55.38M | $48.34M | $39.52M | -$95.96M |
| Financing cash flow | $25.77M | $19.99M | -$2.61M | $166.96M | $7.40M | $238,000 | -$951,000 | $151.69M |
| Depreciation & amortization | $765,000 | $690,000 | $636,000 | $698,000 | $576,000 | $538,000 | $497,000 | $467,000 |
| Stock-based compensation | $11.87M | $10.40M | $11.64M | $6.75M | $6.43M | $6.88M | $7.82M | $7.90M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.